|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: GPM6B |
Gene summary for GPM6B |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | GPM6B | Gene ID | 2824 |
| Gene name | glycoprotein M6B | |
| Gene Alias | M6B | |
| Cytomap | Xp22.2 | |
| Gene Type | protein-coding | GO ID | GO:0001503 | UniProtAcc | Q13491 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 2824 | GPM6B | LZE24T | Human | Esophagus | ESCC | 6.55e-06 | 1.28e-01 | 0.0596 |
| 2824 | GPM6B | P8T-E | Human | Esophagus | ESCC | 5.44e-03 | 6.73e-01 | 0.0889 |
| 2824 | GPM6B | P10T-E | Human | Esophagus | ESCC | 3.41e-03 | 1.47e-01 | 0.116 |
| 2824 | GPM6B | P11T-E | Human | Esophagus | ESCC | 6.06e-17 | 2.06e+00 | 0.1426 |
| 2824 | GPM6B | P16T-E | Human | Esophagus | ESCC | 5.44e-13 | 2.85e-01 | 0.1153 |
| 2824 | GPM6B | P19T-E | Human | Esophagus | ESCC | 1.27e-09 | 2.63e+00 | 0.1662 |
| 2824 | GPM6B | P24T-E | Human | Esophagus | ESCC | 1.13e-07 | 4.90e-01 | 0.1287 |
| 2824 | GPM6B | P26T-E | Human | Esophagus | ESCC | 6.42e-03 | 8.79e-02 | 0.1276 |
| 2824 | GPM6B | P27T-E | Human | Esophagus | ESCC | 5.68e-03 | 2.47e-02 | 0.1055 |
| 2824 | GPM6B | P32T-E | Human | Esophagus | ESCC | 2.44e-10 | 8.99e-01 | 0.1666 |
| 2824 | GPM6B | P37T-E | Human | Esophagus | ESCC | 2.76e-03 | 3.30e-01 | 0.1371 |
| 2824 | GPM6B | P42T-E | Human | Esophagus | ESCC | 4.31e-02 | 4.95e-01 | 0.1175 |
| 2824 | GPM6B | P44T-E | Human | Esophagus | ESCC | 1.63e-07 | 8.64e-01 | 0.1096 |
| 2824 | GPM6B | P52T-E | Human | Esophagus | ESCC | 1.84e-05 | 2.07e-01 | 0.1555 |
| 2824 | GPM6B | P54T-E | Human | Esophagus | ESCC | 1.51e-06 | 3.00e-01 | 0.0975 |
| 2824 | GPM6B | P61T-E | Human | Esophagus | ESCC | 1.07e-05 | 5.75e-01 | 0.099 |
| 2824 | GPM6B | P76T-E | Human | Esophagus | ESCC | 1.42e-08 | 2.14e-01 | 0.1207 |
| 2824 | GPM6B | P79T-E | Human | Esophagus | ESCC | 4.90e-05 | 1.83e-01 | 0.1154 |
| 2824 | GPM6B | P107T-E | Human | Esophagus | ESCC | 1.22e-07 | 4.43e-01 | 0.171 |
| 2824 | GPM6B | P128T-E | Human | Esophagus | ESCC | 8.35e-03 | 7.61e-02 | 0.1241 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0150115110 | Esophagus | ESCC | cell-substrate junction organization | 77/8552 | 101/18723 | 3.46e-10 | 9.57e-09 | 77 |
| GO:000704418 | Esophagus | ESCC | cell-substrate junction assembly | 73/8552 | 95/18723 | 5.27e-10 | 1.35e-08 | 73 |
| GO:003158919 | Esophagus | ESCC | cell-substrate adhesion | 221/8552 | 363/18723 | 3.06e-09 | 6.62e-08 | 221 |
| GO:001081020 | Esophagus | ESCC | regulation of cell-substrate adhesion | 144/8552 | 221/18723 | 3.55e-09 | 7.45e-08 | 144 |
| GO:004804116 | Esophagus | ESCC | focal adhesion assembly | 65/8552 | 87/18723 | 3.28e-08 | 6.08e-07 | 65 |
| GO:0032970111 | Esophagus | ESCC | regulation of actin filament-based process | 231/8552 | 397/18723 | 2.91e-07 | 4.20e-06 | 231 |
| GO:0032956111 | Esophagus | ESCC | regulation of actin cytoskeleton organization | 210/8552 | 358/18723 | 4.40e-07 | 6.00e-06 | 210 |
| GO:000195217 | Esophagus | ESCC | regulation of cell-matrix adhesion | 85/8552 | 128/18723 | 1.70e-06 | 2.02e-05 | 85 |
| GO:000150317 | Esophagus | ESCC | ossification | 232/8552 | 408/18723 | 3.00e-06 | 3.40e-05 | 232 |
| GO:000716018 | Esophagus | ESCC | cell-matrix adhesion | 141/8552 | 233/18723 | 3.33e-06 | 3.71e-05 | 141 |
| GO:015011619 | Esophagus | ESCC | regulation of cell-substrate junction organization | 51/8552 | 71/18723 | 6.99e-06 | 7.04e-05 | 51 |
| GO:19038289 | Esophagus | ESCC | negative regulation of cellular protein localization | 76/8552 | 117/18723 | 1.97e-05 | 1.72e-04 | 76 |
| GO:005189318 | Esophagus | ESCC | regulation of focal adhesion assembly | 47/8552 | 66/18723 | 2.31e-05 | 1.98e-04 | 47 |
| GO:009010918 | Esophagus | ESCC | regulation of cell-substrate junction assembly | 47/8552 | 66/18723 | 2.31e-05 | 1.98e-04 | 47 |
| GO:00301984 | Esophagus | ESCC | extracellular matrix organization | 171/8552 | 301/18723 | 6.08e-05 | 4.67e-04 | 171 |
| GO:00430624 | Esophagus | ESCC | extracellular structure organization | 171/8552 | 302/18723 | 7.73e-05 | 5.76e-04 | 171 |
| GO:00452294 | Esophagus | ESCC | external encapsulating structure organization | 172/8552 | 304/18723 | 7.80e-05 | 5.80e-04 | 172 |
| GO:003432918 | Esophagus | ESCC | cell junction assembly | 227/8552 | 420/18723 | 3.06e-04 | 1.83e-03 | 227 |
| GO:00850292 | Esophagus | ESCC | extracellular matrix assembly | 29/8552 | 45/18723 | 8.63e-03 | 3.04e-02 | 29 |
| GO:190188810 | Esophagus | ESCC | regulation of cell junction assembly | 109/8552 | 204/18723 | 1.53e-02 | 4.96e-02 | 109 |
| Page: 1 2 3 4 5 6 7 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| GPM6B | SNV | Missense_Mutation | novel | c.724N>A | p.Gly242Arg | p.G242R | Q13491 | protein_coding | tolerated(0.06) | probably_damaging(1) | TCGA-A2-A3Y0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
| GPM6B | SNV | Missense_Mutation | c.31N>C | p.Glu11Gln | p.E11Q | Q13491 | protein_coding | deleterious_low_confidence(0.05) | benign(0.1) | TCGA-C8-A138-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| GPM6B | SNV | Missense_Mutation | c.5N>G | p.Lys2Arg | p.K2R | Q13491 | protein_coding | deleterious_low_confidence(0.03) | probably_damaging(0.98) | TCGA-EW-A1IZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | SD | |
| GPM6B | SNV | Missense_Mutation | c.499N>A | p.Ala167Thr | p.A167T | Q13491 | protein_coding | tolerated(0.72) | benign(0.241) | TCGA-LD-A74U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | taxotere | SD | |
| GPM6B | SNV | Missense_Mutation | novel | c.615G>T | p.Trp205Cys | p.W205C | Q13491 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-PL-A8LV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| GPM6B | SNV | Missense_Mutation | rs776965626 | c.307N>A | p.Val103Met | p.V103M | Q13491 | protein_coding | tolerated(0.25) | benign(0.075) | TCGA-LP-A7HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| GPM6B | SNV | Missense_Mutation | c.412N>C | p.Phe138Leu | p.F138L | Q13491 | protein_coding | deleterious(0) | probably_damaging(0.927) | TCGA-F4-6703-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| GPM6B | SNV | Missense_Mutation | novel | c.838N>T | p.Ile280Phe | p.I280F | Q13491 | protein_coding | tolerated(0.19) | benign(0.015) | TCGA-A5-A7WJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| GPM6B | SNV | Missense_Mutation | rs745969304 | c.364N>A | p.Glu122Lys | p.E122K | Q13491 | protein_coding | tolerated(0.37) | benign(0.052) | TCGA-AJ-A3BH-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
| GPM6B | SNV | Missense_Mutation | novel | c.479N>C | p.His160Pro | p.H160P | Q13491 | protein_coding | tolerated(0.07) | probably_damaging(0.95) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |